Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates
Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.
EP. 1: Treatment Strategies for NSCLC with Non-Actionable Mutations
June 24th 2024Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.
EP. 2: Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02
June 24th 2024Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.
%201%20(1)-Recovered-Recovered%20copy.jpg?fit=crop&auto=format)
%201%20(1)-Recovered-Recovered%20copy.jpg?fit=crop&auto=format)
